Search
sintilimab
Indications:
- non-small cell lung cancer (NSCLC)
- advanced gastric cancer* [3]
- gastroesophageal junction adenocarcinoma* [3]
* aded to chemotherapy
Dosage:
- 200 mg every 3 weeks for up to 2 years
Mechanism of action:
- fully human IgG4 monoclonal antibody PD-1 inhibitor
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
antineoplastic agent (chemotherapeutic agent)
References
- Sternberg A
Sintilimab Moves Forward With FDA Acceptance of Application in Nonsquamous NSCLC.
CancerNetwork. May 18, 2021
https://www.cancernetwork.com/view/sintilimab-moves-forward-with-fda-acceptance-of-application-in-nonsquamous-nsclc
- Davenport L
Triple Therapy for Squamous NSCLC Shows Real-World Clinical Benefit.
Medscape. December 23, 2021
https://www.medscape.com/viewarticle/965488
- Xu J, Jiang H, Pan Yet al
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal
Junction Cancer. The ORIENT-16 Randomized Clinical Trial.
JAMA. 2023;330(21):2064-2074. Dec 5
PMID: 38051328
https://jamanetwork.com/journals/jama/fullarticle/2812482